Systemic Content of Eicosanoids in Patients with Chronic Obstructive Pulmonary Disease Concomitant with Coronary Heart Disease

Anatoly Yachnik¹, Sergij Shuper², Vira Shuper³

¹Leading researcher at the National Institute of Physiologo
and Pulmonology named after F.G. Yanovsky, Kiev, Ukraine,

²Department of the internal medicine, clinical pharmacology and occupational diseases,
Higher State Educational Establishment of Ukraine
“Bukovinian State Medical University”, Chernivtsi, Ukraine

³Department of the internal medicine, clinical pharmacology and occupational diseases,
Higher State Educational Establishment of Ukraine
“Bukovinian State Medical University”, Chernivtsi, Ukraine

Abstract: The often-occurring combination of chronic obstructive pulmonary disease, combined with coronary heart disease, aggravates the course of the underlying disease, changes the approaches to treatment, and recently serves as an object of scientific research. For effective treatment of this comorbidity it is necessary to study the fine mechanisms of pathogenesis, in particular, the state of eicosanoids, such as leukotriene B₂ (LTB₂) and thromboxane (Tx) A₂, which affect the level of systemic inflammation and aggregation of thrombocytes.

The aim of the investigation was to study the content of eicosanoids – leukotriene B₂ and thromboxane A₂ (by stable metabolite TxB₂) in the blood serum and urine in patients with COPD, combined with CHD.

Material and methods of the research. There were investigated 37 patients with exacerbation of COPD (clinical group B, GOLD II) associated with CHD – the main group, 27 patients with exacerbation of COPD (Iª comparison group) and 30 patients with coronary heart disease, stable angina pectoris (IIª comparison group).

Levels of TxB₂ and LTB₄ in the blood serum and urine were examined in all patients and 32 healthy volunteers, using certified in Ukraine reagents TxB2 and LTB4 ELISA kit (Enzo Life Sciences, USA) by the method of enzyme immunoassay.

Results and discussion. In the blood serum of patients with COPD associated with CHD, the highest concentrations of LTB₄ and TxB₂ were marked, comparing to patients with COPD without CHD and with CHD without COPD that was accompanied by increasing of their excretion with urine. The strength and direction of correlation links between concentrations of these eicosanoids in blood serum and indices of bronchial patency indicate their negative influence at bronchial patency of patients with a combination of COPD and CHD. Correlations between concentrations of LTB₄ and TxB₂ in the blood serum in patients with combined pathology confirm their mutually reinforcing effect to systemic inflammation according to their biological actions.

Keywords: leukotrienes, thromboxane, COPD, coronary heart disease.

1. Introduction

Comorbidity is now a characteristic feature of modern internal medicine and pulmonology [1 – 8]. An unfavorable ecological situation, bad habits, chronic stresses, irrational nutrition, aging of the population cause development of the color morbidology. The coexistence of two or more different diseases influences on the course of each of them, causing difficulties in the selection of therapy, increases the risk of complications, and worsens the prognosis for the patient. The close anatomo-physiological relationship of the respiratory and cardiovascular systems in patients over the age of 40 years contributes to the frequent combination of chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD) [10]. The number of patients with COPD is steadily increasing. In persons over 40 years, the morbidity of COPD rises to 10.1%. Nowadays COPD has the 4th place among all causes of death, accounting for 4% in their overall structure. By 2020, it is expected that COPD will move to 3rd place as the cause of death in the world [7].

Coronary heart disease (CHD) and heart failure (HF) become among the leading, but not always timely diagnosed, causes of death in patients with COPD. According to large-scale population-based studies, the risk of death from cardiovascular disease in patients with COPD is increased by 2-3 times and accounts for about 50% of the total number of deaths [4]. In patients with COPD, the frequency of hospitalizations due to cardiovascular disease is higher than only because of COPD. At the same time, heart failure and coronary heart disease serve as the most frequent reasons for the need of patients in hospital care [1]. Deeper understanding of the subtle mechanisms of development of co-morbidity and complications in COPD, as well as the impact on them can improve the results of treatment and prognosis for the patient. The most formidable predictor of fatal complications in COPD associated with coronary heart disease is myocardial infarction as a consequence of thrombotic complications in the microcirculatory system. Aggregation of thrombocytes is stimulated by eicosanoids, which are the products of metabolism of arachidonic acid. Systemic chronic inflammation in COPD stimulates the production of a large
number of inflammatory mediators [5], among which leukotrienes play an important role, in particular, leukotriene B4 (LTB4) (a product of neutrophil leukocytes) and thromboxanes (TX) (platelet aggregation stimulators). In patients with COPD [6], with CHD [2], as well as in cases of the combination of broncho-obstructive diseases with CHD [11], the negative role of increasing platelet aggregation capacity in the development of microcirculation disorders was shown, as well as the adverse effect of elevation of the leukotriene B4 content to the bronchial patency [9]. The investigation of the role of eicosanoids - important mediators of the inflammatory cascade in the progression of COPD, combined with CHD, as well as the search for effective ways of influencing them, will increase the results of treatment and the quality of life of patients with comorbidity of COPD and CHD.

2. The purpose of the study

was to investigate the content of eicosanoids - leukotriene B4 and thromboxane A2 (stable metabolite B2) in the blood serum and urine of patients with COPD combined with CHD. The research was carried out in accordance with the basic plan of scientific research works of the Higher State Educational Establishment "Lugansk State Medical University" and has been a fragment of the research topic "Clinical and pathogenic features of the combined pathology of internal organs, their treatment and prognosis of the course" (State Registration No. 0109U002725).

3. Material and methods of investigation.

The study involved 37 patients of the middle age (54.6 ± 3.3) years with exacerbation of COPD (clinical group B, GOLD II) associated with CHD - the main group who underwent inpatient treatment in 2012-2013 in therapeutic hospitals of Lugansk. 27 patients with COPD in the stage of exacerbation (Ist comparison group) and 30 patients with CHD, stable angina pectoris (IInd comparison group) made up the comparison groups. To develop the reference norm, 32 practically healthy volunteers were examined. The age and gender composition of the comparison groups, as well as healthy volunteers, corresponded to those in the main group. Diagnosis of COPD and CHD, the volume of their treatment was established in accordance with existing protocols. All patients underwent spirometric examination with spirometer "Spirobank" (MIR, Italy), electrocardiographic examination. All patients, as well as healthy volunteers, were examined for serum and urine level of TxB2 with the use of the Ukrainian-certified reagent TxB2 ELISA kit (Enzo Life Sciences, USA) using the enzyme immunoassay (ELISA). The determination of LTB4 in the blood serum and urine of the subjects was also performed by ELISA using the "LTB4 ELISA kit" (Enzo Life Sciences, USA) reagent.

Statistical processing of the received data was carried out using licensed software products of Microsoft Office Professional 2003, the license of Russian Academic OPEN No Level No. 17016297. To verify the correspondence between the distributions of the values of the series of measurements for the normal distribution the function NORMSAMP-1 in Microsoft Excel was used. On that bases the parametric (t-test of reliability of Student) or nonparametric (Wilcoxon test) statistical methods [3] with an estimation of reliability of the received results of researches at the set level of significance p ≤ 0.05 were chosered.

4. Results and discussion.

In all patients with COPD, included in the study, in admission to the inpatient department the exacerbation of disease was diagnosed. The main manifestations were – the respiratory syndrome in 100% of patients with COPD, intoxication - in 32 patients (84.5%) of the main group and 22 patients (81.5%) in the I° group of comparison, cardiac - in 100% patients of the main group, in 13 patients (48.1%) of the 1st comparison group and in 100% of cases in the II° comparison group. Periodic increase of arterial pressure was noted in 11 (29.7%) patients in the main group, 8 (29.6%) in the 1st comparison group and in 9 cases (30%) in the II° comparison group. The astheno-neurotic syndrome was found in 31 patients (83.8%) of the main group, in 19 patients (70.4%) of the I° comparison group and in 14 patients (46.7%) of the II° comparison group. Cardiac syndrome occurred in all patients of the main group and II° group of comparison. In 7 (25.9%) patients from group I, cardiac complaints were manifested by periodic palpitation on the background of frequent use of inhaled bronchodilators with β2-agonists. In patients with COPD, combined with CHD, the average range of the forced expiratory volume in the first sec. (FEV1) was (67.7 ± 3.4) %, the post-dilatation FEV1/FVC was equal to (69.3 ± 4.1)%.

In the patients of I° comparison group FEV1 reached (69.4 ± 3.6)% post-dilatation FEV1/FVC - (70.9 ± 3.7)%. In the patients of II° comparison group FEV1 was equal to (83.4 ± 4.1)%, post-dilatation FEV1/FVC - (79.4 ± 3.3)%.

The concentration of TxB2 in the blood serum reached (3382.3 ± 290.8) pg/ml in the patients of the main group (see Table 1), exceeding the average level of healthy volunteers by 22.2 times (p <0.001), the same parameter with exacerbation of COPD without CHD by 2.2 times (p <0.01) and by 1.4 times (p <0.05) in patients with CHD.

The concentration of TxB2 in the blood serum of patients from the 1st comparison group was the lowest among all examined patients, however, it exceeded the reference norm by 10 times (p <0.001).

Table 1: TxB2 content in blood serum and urine of the examined individuals (M ± m)

<table>
<thead>
<tr>
<th>Material for study</th>
<th>Healthy people (n=32)</th>
<th>Main group (n=37)</th>
<th>Comparison groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood serum, pg/ml</td>
<td>152.4 ± 19.2</td>
<td>3382.3 ± 290.8*</td>
<td>1529.2 ± 101.3*</td>
</tr>
<tr>
<td>Urine, pg/ml</td>
<td>131.5 ± 12.7</td>
<td>183.6 ± 13.2*</td>
<td>297.4 ± 19.3*</td>
</tr>
</tbody>
</table>

Note: * -p <0.05 when compared with healthy subjects.

In the same time, the average level of TxB2 concentration was higher in 1.5 times in patients from the IInd comparison group (p <0.05). This difference in the TxB2 concentrations between patients with COPD and CHD can be explained by the more significant production of this eicosanoid by activated blood cells and platelets because of their pronounced tendency to aggregation in the development of CHD [2] – [6], while in case of COPD, the circulatory disorders could be influenced by sludge of thrombocytes. In patients from group II of comparison, the level of TxB2 in the blood serum was reliably higher than in healthy volunteers in 15.4 times, equaling (2347.6 ± 156.3) pg/ml, however, it was less than that in the
main group in 1.4 times (p <0.05). The concentration of TxB₂ in the urine of the patients from the main group (see Table 1) was 183.6 ± 13.2 pg/ml and in 1.4 times higher than in practically healthy individuals (p <0.05). Nevertheless, it was lower than the same parameter in patients of the 1st comparison group in 1.6 times (p <0.05), and reliably less than the value of this eicosanoid in the II comparison group by 2.5 times (p <0.01). In the urine of patients from the 1st comparison group, the concentration of TxB₂ exceeded the norm by 2.3 times (p <0.01) and was not reliably differ from that in the 2nd comparison group. In patients with coronary artery disease (group II of comparison), the values of TxB₂ in urine were reliably higher than in healthy individuals in 2.5 times, and were not reliably differ from those in group I of comparison.

The content of LTB₄ in the blood serum and urine of the examined persons is presented in Table 2.

In patients from the main group, the serum LTB₄ content was the highest among all examined patients, reaching (6678.0 ± 375.4) pg/ml and exceeding the norm by 20.3 times (p <0.001). Evidently, systemic inflammation in COPD, combined with inflammatory manifestations in CHD, provided maximum concentration of this eicosanoid in the blood serum [5].

### Table 2: LTB₄ content in blood serum and urine of the examined individuals (M ± m)

<table>
<thead>
<tr>
<th>Material for study</th>
<th>Healthy people (n=32)</th>
<th>Main group (n=37)</th>
<th>Comparison groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>I (n=27)</td>
</tr>
<tr>
<td>Blood serum, pg/ml</td>
<td>329.4±31.6</td>
<td>6678.0±375.4*</td>
<td>5142.6±284.2*</td>
</tr>
</tbody>
</table>
| Urine, pg/ml      | 59.7±5.1               | 208.5±12.9*      | 139.7±10.6*      | 89.5±7.2*       *

Note: * - p <0.05 when compared with the parameters of healthy people

Some studies of LTB₄ in bronchial obstructive diseases indicated the pro-inflammatory role of LTB₄, produced mainly by activated neutrophils, and the need to find ways of the rational correction of that [8]. In patients from the 1st comparison group, the concentration of LTB₄ was in 15.6 times higher than the reference norm (p <0.001), but less than the same parameter in the main group in 1.3 times (p <0.05) and more than in the II comparison group of comparison in 3.9 times (p <0.01). In group II of comparison, the serum level of LTB₄ was the lowest, reaching (1728.3 ± 118.4) pg/ml, but was in 5.2 times higher than in healthy subjects (p <0.01). The concentration of LTB₄ in the urine of the patients from the main group was (208.5 ± 12.9) pg/ml, exceeding the reference norm by 3.5 times (p <0.01). The concentration of this eicosanoid in the urine of the patients from the 1st comparison group was in 1.5 times (p <0.01) less than in practically healthy individuals, reaching (139.7 ± 10.6) pg ml and by 1.5 times reliably exceeding the same parameter in persons of group II of comparison. At the same time, the content of LTB₄ in the urine of the patients from the II comparison group, although it was the lowest (89.5 ± 7.2) pg/ml, however, it was in 1.5 times higher the norm (p <0.05). The increased content of this eicosanoid in the urine as a way of excretion of products of the inflammatory reaction, can serve as a confirmation of the systemic inflammation activity in the body of patients with CHD.

When analyzing the correlation between the bronchial patency rates and the level of LTB₄, it was found that negative correlation of the mean force (r = - 0.543, p <0.05) presents between the FEV₁ and the serum level of LTB₄ in the patients from the main group. At the same time, in the I comparison group, this correlation was somewhat weaker (r = - 0.389, p <0.05) and was absent in patients of the II comparison group.

Only weak negative correlation was found between the level of bronchial patency and the concentration of TxB₂ in the blood serum in the patients of the main group (r = - 0.347, p <0.05). At the same time, positive correlation of different degrees were noted between the serum concentrations of the investigated eicosanoids in patients of all groups. The strongest one (r = + 0.614, p <0.05) was observed in the patients of the main group, slightly weaker - in the patients of the I comparison group (r = + 0.528, p <0.05) and weak - in the patients of the II comparison group (r = + 0.356, p <0.05). In our opinion, the existence of these correlation links between serum concentrations of the investigated eicosanoids in patients, taking into account the directivity of their biological effects, confirms their interaction, which enhances systemic inflammation, and needs to find ways of correction.

Thus, in the blood serum of patients with COPD associated with CHD, the concentrations of LTB₄ and TxB₂ are highest, compared with patients with COPD without CHD and CHD without COPD, which is accompanied by the rising of their excretion with urine. The strength and direction of the correlation links between the concentrations of these eicosanoids in the blood serum and bronchial patency indices indicate their negative effect on the bronchial patency of patients with the comorbidity of COPD and CHD. Correlation between the concentrations of LTB₄ and TxB₂ in the blood serum in patients with combined pathology confirms the synergistic effect of these eicosanoids on systemic inflammation, taking into account the biological direction of the action.

### 5. Conclusions

1. The reliably growth of the LTB₄ concentration in the blood serum was Identified in patients with exacerbation of COPD associated with coronary heart disease, exceeding by 20.3 times the norm, by 1.3 times the same parameter in patients with COPD without CHD and by 3.9 times - than in the patients with CHD itself (p <0.05). The urine level of LTB₄ was also elevated in all examined patients with the highest values in the main group.

2. The TxB₂ content in the blood serum of the patients from the main group was the highest and in 22.2 times higher than the norm, in 2.2 times higher than the same one in patients with COPD and in 1.4 times – than in patients with coronary heart disease (p <0.05). The urine level of TxB₂ was also elevated in all examined patients in all examined patients.

3. The direction of the correlation links between concentrations of these eicosanoids in the blood serum and FEV₁ indicates their adverse effect to the bronchial patency of patients with COPD, while the interrelationship of LTB₄ with TxB₂ shows the mutual potentiating effect of these mediators on the systemic inflammation.

### References


[2] Л.И. Бурячкова, Е.О. Полякова, А.В. Зорин [и др.]
Активация тромбоцитов и маркеры воспаления у больных ишемической болезнью сердца с депрессией», Терапевт. Архив, №10, С. 9–14, 2006.


Anatoly Yachnik - doctor of medical sciences, professor. Leading researcher at the National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky. Directions of his scientific activity are pulmonology, cardiology. He is the author of more than 150 scientific works, including 2 monographs, more than 15 inventions and useful models, 3 rationalization proposals, many informational letters and methodical recommendations.

Sergij Shuper, graduated from Lugansk State Medical University, Ukraine, Doctor of Philosophy in Medicine, assistant professor. He is the author of more than 70 publications on the problems of internal medicine and comorbid pathology. Corresponding author

Vira Shuper, graduated from Lugansk State Medical University, Ukraine, Doctor of Philosophy in Medicine, associated professor. She is the author of more than 70 publications on the problems of internal medicine including 3 manuals recommended by the Ministry of Health and Ministry of Education and Science of Ukraine. The main direction of scientific research is a comorbid therapeutic pathology.